ANGELA HARPER: Open Payments
NPI 1801860515 · COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$801 in 53 payments from 11 companies in 2025. Trend: 2023 $434 · 2024 $993 · 2025 $801
Food & beverage: $801
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 13 | $246 |
| ABBVIE INC. | 23 | $206 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $81 |
| Alkermes, Inc. | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Bausch Health US, LLC | 2 | $49 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $15 |
Products named: INGREZZA, VRAYLAR, REXULTI, CAPLYTA, APLENZIN, LYBALVI, HETLIOZ, ARISTADA.
Industry payments across SC — which companies pay providers there.
